Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

Raymond James ups Protech Home Medical PT to $3 (Canadian) from $2.00

Raymond James raised its price target for Protech Home Medical (TSXV:PTQ) to $3 (Canadian) from $2.00, citing an update to its valuation methodology. The stock closed at $2.05 on Jan. 21. Protech is a provider of...

January 22, 2021

Markets

BTIG cuts Senseonics to neutral from buy; removes PT

BTIG downgraded Senseonics Holdings (NYSE American:SENS) to “neutral” from “buy” and removed its price target, citing Senseonics’ stock price, which has soared about 500% over the past month. The stock closed at $2.67...

January 21, 2021

Markets

Canaccord ups Neuronetics PT to $20 from $8

Canaccord Genuity raised its price target for Neuronetics (NASDAQ:STIM) to $20 from $8, reflecting the company’s strong fourth quarter preliminary financial results and a new focus on high-margin utilization, compared...

January 19, 2021

Markets

HCW ups XOMA PT to $56 from $30

H.C. Wainwright raised its price target for XOMA (NASDAQ:XOMA) to $56 from $30, citing the company’s growing asset base, which is linked to both increasing levels of milestone payments and future royalty potential from...

January 19, 2021

Markets

SVB Leerink ups NextGen Healthcare PT to $21 from $14

SVB Leerink raised its price target for NextGen Healthcare (NASDAQ:NXGN) to $21 from $14, citing unaudited preliminary fiscal third quarter results ended Dec. 31, 2020 that beat Street estimates and higher fiscal 2021...

January 13, 2021

Markets

Mackie starts Newtopia at speculative buy; PT $1.10 (Canadian)

Mackie Research Capital initiated coverage of Newtopia (TSXV:NEWU) with a “speculative buy” rating and price target of $1.10 (Canadian). The stock closed at 62 cents on Jan. 11. Newtopia is a fast-growing healthcare...

January 12, 2021

Markets

Stifel starts Neoleukin Therapeutics at buy; PT $18

Stifel launched coverage of Neoleukin Therapeutics (NASDAQ:NLTX) with a “buy” rating and $18 price target. The stock closed at $14.61 on Jan. 5. Neoleukin is creating next generation immunotherapies primarily for...

January 6, 2021

Markets

BTIG starts Delcath Systems at buy; PT $23

BTIG initiated coverage of Delcath Systems (NASDAQ:DCTH) with a “buy” rating and price target of $23. The stock closed at $16.91 on Jan. 4. Delcath has developed HEPZATO, a percutaneous hepatic perfusion system that “we...

January 5, 2021

Markets

HCW starts Kazia Therapeutics at buy; PT $17

H.C. Wainwright launched coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and price target of $17. The stock closed at $8.98 on Jan. 4. Kazia is developing novel therapies against brain cancer. Its lead...

January 5, 2021

Markets

WB ups VistaGen Therapeutics to OP; fair value estimate $9

William Blair upgraded VistaGen Therapeutics (NASDAQ:VTGN) to “outperform” with a fair value estimate of $9, citing a “clearly skewed risk/reward” for the shares. The stock closed at $1.94 on Dec. 31. VistaGen is...

January 4, 2021

Markets

Leede Jones Gable starts Profound Medical at buy; PT $36.50 (Canadian)

Leede Jones Gable launched coverage of Profound Medical (TSX:PRN) with a “buy” rating and price target of $36.50 (Canadian). The stock gained $2.96, or 13%, to close at $26.18 on Dec. 21. The firm’s flagship device...

December 22, 2020

Markets

Leede Jones Gable starts Protech Home Medical at buy; PT $3.25

Leede Jones Gable initiated coverage of Protech Home Medical (TSXV:PTQ) with a “buy” rating and price target of $3.25. The stock closed at $1.47 on Dec. 18. Protech is a durable medical equipment (DME) and home...

December 21, 2020

Markets

HCW starts Alpine Immune Sciences at buy; PT $21

H.C. Wainwright launched coverage of Alpine Immune Sciences (NASDAQ:ALPN) with a “buy” rating and $21 price target. The stock finished at $14.57 on Dec. 18. Alpine is leading the way in developing protein-based...

December 21, 2020

Markets

HCW starts Arbutus Biopharma at buy; PT $10

H.C. Wainwright launched coverage of Arbutus Biopharma (NASDAQ:ABUS) with a “buy” rating and price target of $10. The stock closed at $4.41 on Dec. 16. Arbutus is primarily focused on discovering, developing and...

December 17, 2020

Markets

Maxim starts Cyclo Therapeutics at buy; PT $12

Maxim Group initiated coverage of Cyclo Therapeutics (NASDAQ:CYTH) with a “buy” rating and $12 price target. The stock closed at $3.85 on Dec. 16. Cyclo is developing a Phase 3-ready hydroxypropyl beta cyclodextrin...

December 17, 2020

Markets

Chardan starts CohBar at buy; PT $3

Chardan Research launched coverage of CohBar (NASDAQ:CWBR) with a “buy” rating and price target of $3. The stock closed at $1.29 on Dec. 16. “We expect that Cohbar’s unique pipeline of mitochondrial derived...

December 17, 2020

Markets

Brookline starts X4 Pharma at buy; PT $21

Brookline Capital Markets launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $21 price target. The stock closed at $6.10 on Dec. 16. X4 Pharmaceuticals is focused on diseases resulting from...

December 17, 2020

Markets

Leede Jones Gable starts IntelGenx at speculative buy; PT $1 (Canadian)

Leede Jones Gable initiated coverage of IntelGenx Technologies (TSXV:IGX) with a “speculative buy” rating and price target of $1.00 (Canadian). The stock closed at 37 cents on Dec. 15. IntelGenx is a thin-film...

December 16, 2020

Markets

Leede Jones Gable starts IMV at speculative buy; PT $10.50 (Canadian)

Leede Jones Gable launched coverage of IMV (TSX:IMV) with a “speculative buy” and price target of $10.50 (Canadian). The stock closed at $4.03 on Dec. 15. IMV’s flagship technology platform is the lipid-based water-free...

December 16, 2020

Markets

Leede Jones Gable starts Liminal BioSciences at hold; PT $4

Leede Jones Gable initiated coverage of Liminal BioSciences (NASDAQ:LMNL) with a “hold” rating and $4 price target. The stock closed at $4.20 on Dec. 15. Liminal is a plasma products and anti-fibrotic small molecule...

December 16, 2020

Markets

Leede Jones Gable starts Oncolytics Biotech at speculative buy; PT $8.50 (Canadian)

Leede Jones Gable launched coverage of Oncolytics Biotech (TSX:ONC) with a “speculative buy” rating and $8.50 (Canadian) price target. The stock closed at $3.07 on Dec. 15. Oncolytics is a cancer-focused virus-based...

December 16, 2020

Markets

Leede Jones Gable starts Medical Facilities at buy; PT $10.50 (Canadian)

Leede Jones Gable initiated coverage of Medical Facilities (TSX:DR) with a “buy” rating and price target of $10.50 (Canadian). The stock closed at $7.32 on Dec. 15. Medical Facilities owns a majority stake in several U...

December 16, 2020

Subscribe